Yes, I am running dbforms with Tomcat 5.0.14 for several months. I had some problems with the logging. Varga Sandor.
Subject: [dbforms] Tomcat 5.0 > > Hi all, > > Just found that Tomcat 5.0 is released. Is anybody outside there who has tested dbforms with tomcat 5? > > Is it running? > > Regards, > Henner > > > > --__--__-- > > Message: 3 > From: "Brent Corona" <[EMAIL PROTECTED]> > Reply-To: "Brent Corona" <[EMAIL PROTECTED]> > To: [EMAIL PROTECTED] > Date: Thu, 04 Dec 2003 21:21:24 -0300 > Subject: [dbforms] AFTER-HOURS TRADING - Breaking News...baldasarre > > > --.8.E5CD_2_E_.FD > Content-Type: text/plain; > Content-Transfer-Encoding: quoted-printable > > AFTER-HOURS TRADING - BREAKING NEWS > > Get Quote - http://quote.money.cnn.com/quote/quote?symbols=3Dhtds > > Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tuberci= > n Toxicity Study and Formation of Scientific Advisory Panel - Wednesday De= > cember 3, 8:04 pm ET > > DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases = > Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for= > the independent medical group conducting the testing for HTTD (HTDS) has = > forwarded the formal Testing Results of Tubercin=AE's Toxicity Trials to H= > TTD. > > Tubercin of five different concentrations was administered to five groups = > of mice. A pathologist at the University of Oklahoma Health Science Center= > performed autopsies. The mice were randomized and only the control mouse = > was known to the pathologist, as stated in the cover letter of the Patholo= > gy Report. > > The report concludes, "All tissues evaluated, visceral organs and the brai= > n were essentially normal in appearance." "The importance of this report i= > s even better than I expected," stated the spokesperson for the medical gr= > oup. "As the testing continues and if the results are similar to those of = > Chemotherapy and or radiation with no harmful side effects, Tubercin has e= > normous potential for the treatment of cancer and the immune system." > > The President and CEO of HTTD, Mr. Colm J. King is in the process of formi= > ng a Scientific Advisory Panel with leading Oncologists and Immunologists = > from prestigious institutions in the U.S. The panel will review the report= > s and results of Tubercin=AE's findings and will report back to Mr. King w= > ith the ongoing reports in layman language for the shareholders. > > "We are continuing to receive promising results regarding Tubercin=AE and = > we're looking forward to additional positive results in the near future," = > stated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is t= > he first step on the way to human clinical trials as well as the first pos= > itive breakthrough conducted in the United States with an independent medi= > cal group for Tubercin=AE. > > Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate= > d ("HTTD") holds the international marketing rights, except South Korea, t= > o Tubercin=AE, a patented immunostimulant developed for combating Cancer u= > nder medical patent (US Patent 6,274,356). The unique properties unlike ot= > her cancer products are clearly stated in the abstract summary of the pate= > nt... "A carbohydrate complex, which is a mixture of low molecular-weight = > polysaccharides of an arabinomannan structure extracted from Mycobacterium= > tuberculosis, is highly effective in treating various cancer patients wit= > hout incurring any adverse side effects." > > > > > > > Statements in this press release that are not historical facts are forward= > -looking statements within the meaning of the Securities Act of 1933, as a= > mended. Those statements include statements regarding the intent, belief o= > r current expectations of the Company and its management. Such statements = > reflect management's current views, are based on certain assumptions and i= > nvolve risks and uncertainties. Actual results, events, or performance may= > differ materially from the above forward-looking statements due to a numb= > er of important factors, and will be dependent upon a variety of factors, = > including, but not limited to, our ability to obtain additional financing = > and access funds from our existing financing arrangements that will allow = > us to continue our current and future operations and whether demand for ou= > r product and testing service in domestic and international markets will c= > ontinue to expand. The Company undertakes no obligation to publicly update= > these forward-looking statements to reflect events or circumstances that = > occur after the date hereof or to reflect any change in the Company's expe= > ctations with regard to these forward-looking statements or the occurrence= > of unanticipated events. > > > > > > > > > > > > > > > > > > > > > > > > > > > > nlrikxvw lut > ssd > > --.8.E5CD_2_E_.FD-- > > > > > --__--__-- > > _______________________________________________ > jDbForms-interest mailing list > [EMAIL PROTECTED] > https://lists.sourceforge.net/lists/listinfo/jdbforms-interest > > > End of jDbForms-interest Digest > ------------------------------------------------------- This SF.net email is sponsored by: IBM Linux Tutorials. Become an expert in LINUX or just sharpen your skills. Sign up for IBM's Free Linux Tutorials. Learn everything from the bash shell to sys admin. Click now! http://ads.osdn.com/?ad_id=1278&alloc_id=3371&op=click _______________________________________________ DbForms Mailing List http://www.wap-force.net/dbforms
